Gilead Sciences Announces Acquisition of Cancer Drug Developer Arcellx
The deal includes $115 per share in cash, along with a contingent value right of $5 per share.
The acquisition is designed to fully realize the long-term potential of anito-cel, an investigational cell therapy targeting patients with multiple myeloma.
Kite, a subsidiary of Gilead, has already partnered with Arcellx to jointly develop and commercialize this innovative immunotherapy treatment.
Gilead Chairman and CEO Daniel O'Day said that the agreement reflects the company’s belief in the therapy’s potential to benefit cancer patients.
The US Food and Drug Administration has previously accepted the biological license application for anito-cel, with an expected action date of December 23, 2026.
The boards of both companies approved the transaction, which is expected to close in the second quarter of 2026.
Before announcing the acquisition, Gilead already held roughly 11.5% of Arcellx’s outstanding common stock.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
